Literature DB >> 2188874

Health status in inflammatory bowel disease. Biological and behavioral considerations.

J W Garrett1, D A Drossman.   

Abstract

The existing clinical measures of disease activity for inflammatory bowel disease are insufficient to explain a patient's illness experience or health outcomes. Although many disease activity measures have been devised, they are not widely accepted by clinicians because existing ones are no better than a carefully obtained clinical assessment. Furthermore, health status is determined not only by disease activity, but also by the psychological state, cultural influences, degree of social support, and effects of complications, previous surgery, and medication. To develop more accurate appraisals of the impact and severity of IBD, we must prospectively evaluate the biological and psychosocial measures that predict clinically relevant outcomes. We should then be able to develop statistically weighted scales related to specific outcome variables. Such knowledge will help us to develop more sensitive measures of illness, particularly in patients with mild disease for whom present indices are insensitive. This type of assessment should also aid in the understanding of health care utilization, medical vs. surgical options, resource allocation, and the efficacy of therapeutic trials.

Entities:  

Mesh:

Year:  1990        PMID: 2188874     DOI: 10.1016/0016-5085(90)91234-w

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  15 in total

1.  The effect of ageing on function and quality of life in ileal pouch patients: a single cohort experience of 409 patients with chronic ulcerative colitis.

Authors:  Dieter Hahnloser; John H Pemberton; Bruce G Wolff; Dirk R Larson; Brian S Crownhart; Roger R Dozois
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

Review 2.  Quality of life assessment in gastro-oesophageal reflux disease.

Authors:  E J Irvine
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

3.  Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.

Authors:  T Minami; H Tojo; Y Shinomura; S Tarui; M Okamoto
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

4.  Estimation of quality of life in Cypriot patients with inflammatory bowel disease.

Authors:  Maria Tsoukka; Eleni Jelastopulu; Giagkos Lavranos; George Charalambous
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

5.  Psychological Distress and Quality of Life in Pediatric Crohn Disease: Impact of Pain and Disease State.

Authors:  Robyn Lewis Claar; Miranda A L van Tilburg; Bisher Abdullah; Shelby Langer; Dalia Sherif; William E Whitehead; Douglas A Drossman; Rona L Levy
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-10       Impact factor: 2.839

Review 6.  Quality of life measurement in gastrointestinal and liver disorders.

Authors:  M R Borgaonkar; E J Irvine
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

7.  Inflammatory bowel disease: a patient's and caregiver's perspective.

Authors:  F Magro; F Portela; P Lago; J Deus; J Cotter; I Cremers; A Vieira; P Peixe; P Caldeira; H Lopes; R Gonçalves; J Reis; M Cravo; L Barros; P Ministro; M Lurdes Tavares; A Duarte; M Campos; L Carvalho
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

8.  A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity.

Authors:  Douglas A Drossman; Lin Chang; Susan Schneck; Carlar Blackman; William F Norton; Nancy J Norton
Journal:  Dig Dis Sci       Date:  2009-04-01       Impact factor: 3.199

9.  Health status and health care use in persons with inflammatory bowel disease. A national sample.

Authors:  D A Drossman; J Leserman; C M Mitchell; Z M Li; E A Zagami; D L Patrick
Journal:  Dig Dis Sci       Date:  1991-12       Impact factor: 3.199

10.  Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.

Authors:  Paul Rutgeerts; Stefan Schreiber; Brian Feagan; Dorothy L Keininger; Liz O'Neil; Richard N Fedorak
Journal:  Int J Colorectal Dis       Date:  2007-12-11       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.